甲状腺激素治疗强度与卒中发病风险
该回顾性队列研究利用美国退伍军人健康管理局2004至2017年数据,纳入733 208例年龄≥18岁的甲状腺激素使用者,中位随访59个月。结果显示,与外源性甲状腺功能正常相比,外源性甲亢(低TSH或高游离T4)和外源性甲减(高TSH或低游离T4)均与卒中发生率升高相关,且风险随时间累积。
要点
- 外源性甲亢与甲减均与卒中风险升高相关,用药安全需重视。
- TSH<0.1 mIU/L时卒中OR为1.33(95%CI 1.24-1.43)。
- TSH>5.5 mIU/L时卒中OR为1.29(95%CI 1.26-1.33)。
核心结论
- 外源性甲亢和外源性甲减均与卒中风险升高相关,提示应重视患者用药安全。
研究设计与样本
- 回顾性队列研究,使用美国退伍军人健康管理局2004至2017年数据,中位随访59个月。
- 研究人群为733 208例年龄≥18岁的甲状腺激素使用者,均有至少2次TSH测量;其中406 030例有至少2次游离T4测量。
主要发现
- 643 687例中71 333例(11.08%)发生新发心房颤动,663 809例中41 931例(6.32%)发生卒中。
- 校正年龄、性别及既往心房颤动史等因素后,与外源性甲状腺功能正常相比,低TSH或高游离T4与新发卒中风险升高相关。
- 高TSH或低游离T4同样与新发卒中风险升高相关,且外源性甲亢与甲减者的心房颤动和卒中风险均随时间累积。
关键数值与推荐
- 外源性甲亢示例:TSH<0.1 mIU/L时卒中OR 1.33(95%CI 1.24-1.43);游离T4>1.9 ng/dL时OR 1.17(95%CI 1.06-1.30)。
- 外源性甲减示例:TSH>5.5 mIU/L时卒中OR 1.29(95%CI 1.26-1.33);游离T4<0.7 ng/dL时OR 1.29(95%CI 1.22-1.35)。
- 对照为甲状腺功能正常:TSH>0.5-5.5 mIU/L且游离T4 0.7-1.9 ng/dL。
临床怎么用
- 甲状腺激素治疗中应监测TSH和游离T4,避免过度治疗或治疗不足。
- 对TSH或游离T4超出正常范围者,应评估卒中风险并加强随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Stroke is a leading cause of death and disability and there is a need to identify modifiable risk factors. OBJECTIVE: We aimed to determine the relationship between thyroid hormone treatment intensity and incidence of atrial fibrillation and stroke. METHODS: We conducted a retrospective cohort study using data from the Veterans Health Administration between 2004 and 2017, with a median follow-up of 59 months. The study population comprised 733 208 thyroid hormone users aged ≥18 years with at least 2 thyroid stimulating hormone (TSH) measurements between thyroid hormone initiation and incident event (atrial fibrillation or stroke) or study conclusion (406 030 thyroid hormone users with at least 2 free thyroxine [T4] measurements). RESULTS: Overall, 71 333/643 687 (11.08%) participants developed incident atrial fibrillation and 41 931/663 809 (6.32%) stroke. In multivariable analyses controlling for pertinent factors such as age, sex, and prior history of atrial fibrillation, higher incidence of stroke was associated with low TSH or high free T4 levels (ie, exogenous hyperthyroidism; eg, TSH <0.1 mIU/L; OR 1.33; 95% CI, 1.24-1.43; free T4>1.9 ng/dL, OR 1.17, 95% CI 1.06-1.30) and high TSH or low free T4 levels (ie, exogenous hypothyroidism; eg, TSH >5.5 mIU/L; OR 1.29; 95% CI, 1.26-1.33; free T4 <0.7 ng/dL; OR 1.29; 95% CI, 1.22-1.35) compared with euthyroidism (TSH >0.5-5.5 mIU/L and free T4 0.7-1.9 ng/dL). Risk of developing atrial fibrillation and stroke was cumulative over time for both patients with exogenous hyperthyroidism and hypothyroidism. CONCLUSION: Both exogenous hyper- and hypothyroidism were associated with increased risk of stroke, highlighting the importance of patient medication safety.
引用
- Papaleontiou M, Levine DA, Reyes-Gastelum D, et al. Thyroid Hormone Therapy and Incident Stroke. J Clin Endocrinol Metab. 2021. PMID: 34137866. doi:10.1210/clinem/dgab444
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。